These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30989630)

  • 1. Amyloid-β Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena.
    Marcello E; Musardo S; Vandermeulen L; Pelucchi S; Gardoni F; Santo N; Antonucci F; Di Luca M
    Mol Neurobiol; 2019 Oct; 56(10):7136-7143. PubMed ID: 30989630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease.
    Marcello E; Saraceno C; Musardo S; Vara H; de la Fuente AG; Pelucchi S; Di Marino D; Borroni B; Tramontano A; Pérez-Otaño I; Padovani A; Giustetto M; Gardoni F; Di Luca M
    J Clin Invest; 2013 Jun; 123(6):2523-38. PubMed ID: 23676497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAM10 in synaptic physiology and pathology.
    Musardo S; Marcello E; Gardoni F; Di Luca M
    Neurodegener Dis; 2014; 13(2-3):72-4. PubMed ID: 24008925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of EphB2 on Aβ1-42 oligomer-induced neurotoxicity and synaptic NMDA receptor signaling in hippocampal neurons.
    Geng D; Kang L; Su Y; Jia J; Ma J; Li S; Du J; Cui H
    Neurochem Int; 2013 Oct; 63(4):283-90. PubMed ID: 23831214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic dysfunction in Alzheimer's disease: From the role of amyloid β-peptide to the α-secretase ADAM10.
    Musardo S; Marcello E
    Eur J Pharmacol; 2017 Dec; 817():30-37. PubMed ID: 28625569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer's disease.
    Musardo S; Therin S; Pelucchi S; D'Andrea L; Stringhi R; Ribeiro A; Manca A; Balducci C; Pagano J; Sala C; Verpelli C; Grieco V; Edefonti V; Forloni G; Gardoni F; Meli G; Di Marino D; Di Luca M; Marcello E
    Mol Ther; 2022 Jul; 30(7):2474-2490. PubMed ID: 35390543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and Use-Dependent Effects of β-Amyloid Oligomers on NMDA Receptor Function Revealed by Optical Quantal Analysis.
    Sinnen BL; Bowen AB; Gibson ES; Kennedy MJ
    J Neurosci; 2016 Nov; 36(45):11532-11543. PubMed ID: 27911757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions.
    Prox J; Bernreuther C; Altmeppen H; Grendel J; Glatzel M; D'Hooge R; Stroobants S; Ahmed T; Balschun D; Willem M; Lammich S; Isbrandt D; Schweizer M; Horré K; De Strooper B; Saftig P
    J Neurosci; 2013 Aug; 33(32):12915-28, 12928a. PubMed ID: 23926248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bis(propyl)-cognitin Prevents β-amyloid-induced Memory Deficits as Well as Synaptic Formation and Plasticity Impairments via the Activation of PI3-K Pathway.
    Jiang L; Huang M; Xu S; Wang Y; An P; Feng C; Chen X; Wei X; Han Y; Wang Q
    Mol Neurobiol; 2016 Aug; 53(6):3832-3841. PubMed ID: 26160762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM10 as a therapeutic target for brain diseases: from developmental disorders to Alzheimer's disease.
    Marcello E; Borroni B; Pelucchi S; Gardoni F; Di Luca M
    Expert Opin Ther Targets; 2017 Nov; 21(11):1017-1026. PubMed ID: 28960088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NMDAR Antagonist on the Regulation of P-MARCKS Protein to Aβ
    Liu Y; Zhang P; Zheng Y; Yang C; Du T; Ge M; Chang X; Duan R; Ma G
    Neurochem Res; 2018 Oct; 43(10):2008-2015. PubMed ID: 30155805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
    Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
    J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of ADAM10 in Alzheimer's Disease.
    Yuan XZ; Sun S; Tan CC; Yu JT; Tan L
    J Alzheimers Dis; 2017; 58(2):303-322. PubMed ID: 28409746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid beta inhibits ectodomain shedding of N-cadherin via down-regulation of cell-surface NMDA receptor.
    Uemura K; Kuzuya A; Aoyagi N; Ando K; Shimozono Y; Ninomiya H; Shimohama S; Kinoshita A
    Neuroscience; 2007 Mar; 145(1):5-10. PubMed ID: 17257767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity.
    Marcello E; Gardoni F; Mauceri D; Romorini S; Jeromin A; Epis R; Borroni B; Cattabeni F; Sala C; Padovani A; Di Luca M
    J Neurosci; 2007 Feb; 27(7):1682-91. PubMed ID: 17301176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective mechanism underlying phenylethanoid glycosides (PHG) actions on synaptic plasticity in rat Alzheimer's disease model induced by beta amyloid 1-42.
    Jia JX; Yan XS; Song W; Fang X; Cai ZP; Huo DS; Wang H; Yang ZJ
    J Toxicol Environ Health A; 2018; 81(21):1098-1107. PubMed ID: 30430925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell-permeable Aβ1-6A2VTAT(D) peptide reverts synaptopathy induced by Aβ1-42wt.
    Cimini S; Sclip A; Mancini S; Colombo L; Messa M; Cagnotto A; Di Fede G; Tagliavini F; Salmona M; Borsello T
    Neurobiol Dis; 2016 May; 89():101-11. PubMed ID: 26721320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.